April 2010 Announcement: Phase 3 Trials
Apr 02 - 2010 01:52 AM
Following the appointment of Dr. Hans Moebius as Chief Medical Officer, TauRx has undertaken a competitive bid and review process to identify the most suitable partner to take forward its Phase 3 program.
March 2010 Announcement
Mar 11 - 2010 02:03 AM
TauRx Pharmaceuticals Group Company, WisTa Laboratories Ltd, has been notified by the European Patent Office that they are willing to grant a patent for a group of second-generation rember® derivatives discovered by and under development at the Company.
March 2010 Announcement 2
Mar 02 - 2010 02:06 AM
TauRx Announcement: Clinical Trials Initiated Under US IND with Second-Generation form of rember®
February 2010: Pharmawire Interview
Feb 11 - 2010 02:24 AM
Professor Wischik describes plans to take forward late stage clinical development of its second generation Tau Aggregation Inhibitor.
January 2010: Interview With Caledonian Mercury
Jan 11 - 2010 04:30 AM
Prof. Wischik describes aspects of the medical and societal impact of Alzheimer’s disease and the process of developing an AD therapeutic.